A Phase 3 interventional study of Empagliflozin and Placebo in Diabetes Mellitus, Type 1, sponsored by Boehringer Ingelheim. Completed at 189 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-02.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 1.
Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 3rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5 · Phase 4 4
First in 2011; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 977 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 49 across the 12 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 7 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 6 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
1 of the studies testing empagliflozin in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing empagliflozin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Empagliflozin · Drug: Placebo
Drug: Empagliflozin · Drug: Placebo
Drug: Empagliflozin · Drug: Placebo
Drug: Placebo
For blinding purposes
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])
Change from baseline in Glycated hemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))
Change from baseline in Glycated hemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
Rate Per Patient-year of Investigator-reported Symptomatic Hypoglycemic Adverse Events (AEs) With Confirmed Plasma Glucose (PG)
Rate per patient-year of investigator-reported symptomatic hypoglycemic adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycemic AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycemic events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate. This is key secondary endpoints.
Time frame: Week 5 to Week 26, Week 1 to Week 26
Change From Baseline in Body Weight at Week 26
Change from baseline in body weight is presented With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26
Change from baseline in Total daily insulin dose (TDID) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 26
Change from baseline in Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
Time frame: Baseline to week 26
A randomized, placebo-controlled, double-blind, parallel-group study compared 3 doses of empagliflozin (2.5 milligram (mg), 10 mg, and 25 mg) with placebo in patients with type 1 diabetes mellitus (T1DM) as adjunctive to optimized insulin therapy.
| Milestone | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| Started | 242 | 242 | 248 | 245 |
| Treated | 241 | 241 | 248 | 245 |
| Completed | 224 | 232 | 235 | 233 |
| Not completed | 18 | 10 | 13 | 12 |
| Withdrew: Adverse event | 0 | 1 | 2 | 5 |
| Withdrew: Protocol violation | 3 | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 5 | 3 | 3 | 1 |
| Withdrew: Withdrawal by subject | 6 | 1 | 2 | 3 |
| Withdrew: Not treated | 1 | 1 | 0 | 0 |
| Withdrew: Other than specified | 3 | 2 | 5 | 2 |
Change from baseline in Glycated hemoglobin (HbA1c) for full analysis set (FAS) (observed cases \[OC\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
| Percentage (%) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC]) | 0.20 ± 0.05 | -0.09 ± 0.05 | -0.25 ± 0.05 | -0.33 ± 0.05 |
Change from baseline in Glycated hemoglobin (HbA1c) for modified intention-to-treat population set (mITT) (observed case - all data \[OC-AD\]) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
| Percentage (%) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD)) | 0.21 ± 0.05 | -0.06 ± 0.05 | -0.23 ± 0.05 | -0.30 ± 0.05 |
Rate per patient-year of investigator-reported symptomatic hypoglycemic adverse events (AEs) with confirmed plasma glucose (PG) \<54 milligram per deciliter (mg/dL) (\<3.0 millimoles per litre (mmol/L)) and/or severe hypoglycemic AEs (i.e. all investigator-reported AEs that had confirmed PG \<54 mg/dL \[\<3.0 mmol/L\] with symptoms reported and all severe hypoglycemic events that were confirmed by adjudication) is presented for (i) From week 5 to 26 and (ii) From week 1 to 26. Least squares mean is actually an adjusted event rate. This is key secondary endpoints.
| Events per patient year | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| Week 5 to 26 | 6.13 (4.83 to 7.78) | 5.77 (4.53 to 7.34) | 7.37 (5.83 to 9.31) | 6.25 (4.94 to 7.91) |
| Week 1 to 26 | 6.62 (5.30 to 8.27) | 6.17 (4.93 to 7.73) | 8.33 (6.70 to 10.37) | 6.96 (5.58 to 8.67) |
Change from baseline in body weight is presented With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
| Kilogram (kg) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 | 0.21 ± 0.20 | -1.55 ± 0.20 | -2.83 ± 0.20 | -3.22 ± 0.20 |
Change from baseline in Total daily insulin dose (TDID) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
| Unit/kilogram (U/kg) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| Change From Baseline in Total Daily Insulin Dose (TDID) at Week 26 | -0.011 ± 0.007 | -0.060 ± 0.007 | -0.080 ± 0.007 | -0.102 ± 0.007 |
Change from baseline in Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) is presented. With regards to efficacy and safety endpoints, the term 'baseline' referred to the last observed measurement prior to administration of any randomized trial medication. Least squares mean is adjusted mean change from baseline.
| Millimeters of mercury (mmHg) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| SBP | 0.4 ± 0.7 | -1.7 ± 0.7 | -3.5 ± 0.7 | -3.4 ± 0.7 |
| DBP | 0.0 ± 0.4 | -0.4 ± 0.4 | -1.8 ± 0.4 | -1.5 ± 0.4 |
Collected over From the first dose of trial medication until 7 days after last in-take of trial medication, up to 232 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Matching Empagliflozin | 0/241 (0%) | 16/241 (6.6%) | 153/241 (63.5%) |
| Empagliflozin 2.5 Milligram (mg) | 0/241 (0%) | 13/241 (5.4%) | 146/241 (60.6%) |
| Empagliflozin 10 mg | 0/248 (0%) | 21/248 (8.5%) | 172/248 (69.4%) |
| Empagliflozin 25 mg | 1/245 (0.4%) | 16/245 (6.5%) | 162/245 (66.1%) |
| Event | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 2/241 | 2/241 | 6/248 | 5/245 |
| HypoglycaemiaMetabolism and nutrition disorders | 4/241 | 3/241 | 3/248 | 0/245 |
| KetosisMetabolism and nutrition disorders | 0/241 | 1/241 | 0/248 | 3/245 |
| KetoacidosisMetabolism and nutrition disorders | 1/241 | 1/241 | 3/248 | 2/245 |
| Angina unstableCardiac disorders | 0/241 | 2/241 | 0/248 | 0/245 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/241 | 1/241 | 0/248 | 0/245 |
| Abdominal painGastrointestinal disorders | 0/241 | 0/241 | 2/248 | 0/245 |
| VomitingGastrointestinal disorders | 0/241 | 0/241 | 2/248 | 1/245 |
| VertigoEar and labyrinth disorders | 1/241 | 0/241 | 0/248 | 0/245 |
| Eye haemorrhageEye disorders | 1/241 | 0/241 | 0/248 | 0/245 |
| Event | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 144/241 | 137/241 | 162/248 | 151/245 |
| NasopharyngitisInfections and infestations | 24/241 | 23/241 | 22/248 | 26/245 |
| Urinary tract infectionInfections and infestations | 12/241 | 12/241 | 9/248 | 16/245 |
| Blood ketone body increasedInvestigations | 3/241 | 4/241 | 15/248 | 10/245 |
Randomised set (RS): All patients from the Screened set (SCR) who were randomised to trial medication, regardless of whether any trial medication was taken.
| Age, Continuous(Years) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|---|
| Mean | 42.3 ± 13.2 | 43.4 ± 14.3 | 42.3 ± 13.2 | 44.4 ± 13.6 | 43.1 ± 13.6 |
| Sex: Female, Male(Participants) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|---|
| Female | 126 | 120 | 132 | 121 | 499 |
| Male | 116 | 122 | 116 | 124 | 478 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 215 | 220 | 233 | 224 | 892 |
| Not Hispanic or Latino | 27 | 22 | 15 | 21 | 85 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Matching Empagliflozin | Empagliflozin 2.5 Milligram (mg) | Empagliflozin 10 mg | Empagliflozin 25 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 7 | 0 | 1 | 5 | 13 |
| Asian | 2 | 2 | 2 | 5 | 11 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 5 | 3 | 10 | 4 | 22 |
| White | 227 | 234 | 234 | 231 | 926 |
| More than one race | 0 | 3 | 1 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 189 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2015 to primary completion in Sep 2017, 20 months.
Results were first posted in Nov 2018, 1 year 1 month after primary completion. A results delay was requested in Jun 2018.
Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 20 months is above that.
Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin